| Clinical Endpoint . | Per Cent Efficacy . | |||
|---|---|---|---|---|
| 60–80+ y . | 60–69 y . | 70–79 y . | ≥80 y . | |
| HZ | 51 | 64 | 41 | 18 |
| PHN | 66.5 | 65.7 | 66.8 | … |
| Preserving quality of lifea | 66 | 70 | 61 | 59 |
| Clinical Endpoint . | Per Cent Efficacy . | |||
|---|---|---|---|---|
| 60–80+ y . | 60–69 y . | 70–79 y . | ≥80 y . | |
| HZ | 51 | 64 | 41 | 18 |
| PHN | 66.5 | 65.7 | 66.8 | … |
| Preserving quality of lifea | 66 | 70 | 61 | 59 |
Table is based on Oxman et al [9].
Abbreviations: HZ, herpes zoster; PHN, postherpetic neuralgia.
aQuality of life preserved calculated from [56, 57].
| Clinical Endpoint . | Per Cent Efficacy . | |||
|---|---|---|---|---|
| 60–80+ y . | 60–69 y . | 70–79 y . | ≥80 y . | |
| HZ | 51 | 64 | 41 | 18 |
| PHN | 66.5 | 65.7 | 66.8 | … |
| Preserving quality of lifea | 66 | 70 | 61 | 59 |
| Clinical Endpoint . | Per Cent Efficacy . | |||
|---|---|---|---|---|
| 60–80+ y . | 60–69 y . | 70–79 y . | ≥80 y . | |
| HZ | 51 | 64 | 41 | 18 |
| PHN | 66.5 | 65.7 | 66.8 | … |
| Preserving quality of lifea | 66 | 70 | 61 | 59 |
Table is based on Oxman et al [9].
Abbreviations: HZ, herpes zoster; PHN, postherpetic neuralgia.
aQuality of life preserved calculated from [56, 57].
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
